Abnormal kinase signaling can promote other harmful traits, such as neuroinflammation and neuronal cell death. On the other ...

Erasca continues developing novel RAS-pathway cancer drugs, backed by funding through 2027 and promising early results. Find ...

Background Fibrolamellar carcinoma (FLC), a rare and fatal liver cancer lacking effective drug therapy, is driven by the DNAJ ...